Focused Ultrasound and Gemcitabine in Breast Cancer
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a
chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in
patients with early-stage breast cancers. We will be testing the effects of each of these
regimens on cells in the immune system. We hypothesize that the combination of focused
ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will
increase T cell activity. We also hypothesize that focused ultrasound ablation and low-dose
gemcitabine will be safe and will result in non-inferior surgical completion rates and tumor
margin assessments.